Related references
Note: Only part of the references are listed.Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2022)
Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia
G. Dimopoulos et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti et al.
LANCET INFECTIOUS DISEASES (2021)
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
Richard G. Wunderink et al.
LANCET INFECTIOUS DISEASES (2021)
Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis
Jiating Liu et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2021)
Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-ResistantAcinetobacter baumannii: A Prospective, Observational Study
Alessandro Russo et al.
INFECTIOUS DISEASES AND THERAPY (2021)
Synergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii
Jiaqi Cheng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins
Florian Wagenlehner et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
Development of Novel Peptides for the Antimicrobial Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Infection
Joonhyeok Choi et al.
PHARMACEUTICS (2021)
In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant Acinetobacter baumannii
Jacinda C. Abdul-Mutakabbir et al.
ANTIBIOTICS-BASEL (2021)
Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens
Antonio Broncano-Lavado et al.
ANTIBIOTICS-BASEL (2021)
Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
Lei Zha et al.
ADVANCES IN THERAPY (2020)
In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017
Ian Morrissey et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial
Michael S. Niederman et al.
LANCET INFECTIOUS DISEASES (2020)
Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections
Gennaro De Pascale et al.
ANNALS OF INTENSIVE CARE (2020)
Managing Acinetobacter baumannii infections
Jose Garnacho-Montero et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2019)
Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis
Hekun Mei et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
Krystyna M. Kazmierczak et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: A randomised controlled trial
Hye Jung Park et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2019)
Genomic epidemiology of severe community-onset Acinetobacter baumannii infection
Ella M. Meumann et al.
MICROBIAL GENOMICS (2019)
Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis
Konstantinos Z. Vardakas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2018)
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
Mical Paul et al.
LANCET INFECTIOUS DISEASES (2018)
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
Evelina Tacconelli et al.
LANCET INFECTIOUS DISEASES (2018)
Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study
D. Koulenti et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2017)
A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia IASIS Trial
Marin H. Kollef et al.
CHEST (2017)
High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model
Justin R. Lenhard et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Intravenous Minocycline: A Review in Acinetobacter Infections
Sarah L. Greig et al.
DRUGS (2016)
Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014
Lindsey M. Weiner et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2016)
Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis
Wentao Ni et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii
William F. Penwell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance
Zubair A. Qureshi et al.
CLINICAL INFECTIOUS DISEASES (2015)
Comparison of Intrapulmonary and Systemic Pharmacokinetics of Colistin Methanesulfonate (CMS) and Colistin after Aerosol Delivery and Intravenous Administration of CMS in Critically Ill Patients
Matthieu Boisson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
A Review of Intravenous Minocycline for Treatment of Multidrug-Resistant Acinetobacter Infections
David J. Ritchie et al.
CLINICAL INFECTIOUS DISEASES (2014)
Acinetobacter baumannii Emerging as a Multidrug-Resistant Skin and Soft-Tissue Pathogen: Parallels to Methicillin-Resistant Staphylococcus aureus
Brandon L. Adler et al.
JAMA DERMATOLOGY (2014)
Vitamin D status in critically ill patients: the evidence is now bioavailable!
Gennaro De Pascale et al.
CRITICAL CARE (2014)
Colistin Resistance in a Clinical Acinetobacter baumannii Strain Appearing after Colistin Treatment: Effect on Virulence and Bacterial Fitness
Rafael Lopez-Rojas et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial
Emanuele Durante-Mangoni et al.
CLINICAL INFECTIOUS DISEASES (2013)
Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia
H. Aydemir et al.
EPIDEMIOLOGY AND INFECTION (2013)
Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (TEST)
Gerald A. Denys et al.
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2013)
Aerosolized Antibiotics for Ventilator-associated Pneumonia Lessons from Experimental Studies
Jean-Jacques Rouby et al.
ANESTHESIOLOGY (2012)
What Is the Efficacy and Safety of Colistin for the Treatment of Ventilator-Associated Pneumonia? A Systematic Review and Meta-Regression
Diana F. Florescu et al.
CLINICAL INFECTIOUS DISEASES (2012)
Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria
Pinyo Rattanaumpawan et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Jean-Louis Vincent et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Fosfomycin: Use beyond urinary tract and gastrointestinal infections
Matthew E. Falagas et al.
CLINICAL INFECTIOUS DISEASES (2008)
Acinetobacter baumannii skin and soft-tissue infection associated with war trauma
Peter J. Sebeny et al.
CLINICAL INFECTIOUS DISEASES (2008)
High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii
Alex P. Betrosian et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2007)
Multildrug-resistant Acinetobacter infection mortality rate and length of hospitalization
Rebecca H. Sunenshine et al.
EMERGING INFECTIOUS DISEASES (2007)
Impact of Acinetobacter infection on the mortality of burn patients
Michael A. Albrecht et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2006)
Risk factors for adult nosocomial meningitis after craniotomy: Role of antibiotic prophylaxis
Anne-Marie Korinek et al.
NEUROSURGERY (2006)
Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome
AS Leung et al.
CHEST (2006)
Overview of nosocomial infections caused by gram-negative bacilli
R Gaynes et al.
CLINICAL INFECTIOUS DISEASES (2005)
Acinetobacter baumannii ventilator-associated pneumonia:: epidemiological and clinical findings
J Garnacho-Montero et al.
INTENSIVE CARE MEDICINE (2005)
Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin:: A comparison with imipenem-susceptible VAP
J Garnacho-Montero et al.
CLINICAL INFECTIOUS DISEASES (2003)
Share Paper
